No Data
No Data
Realcan Pharmaceutical Group's (SZSE:002589) Solid Earnings Have Been Accounted For Conservatively
Ruikang Pharmaceutical: 2024 Semi-Annual Report Summary
Ruikang Pharmaceutical: 2024 Semi-Annual Report
Realcan Pharmaceutical Group (002589.SZ): The net income in the first half of the year was 31.0253 million yuan, a year-on-year increase of 1.17%.
On August 26, Realcan Pharmaceutical Group (002589.SZ) released its semi-annual report for 2024. During the reporting period, the revenue was 4.032 billion yuan, a decrease of 1.18% compared to the same period last year. The net income attributable to shareholders of the listed company was 31.0253 million yuan, a growth of 1.17% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6.2071 million yuan. The basic earnings per share were 0.0206 yuan.
As of July 19th, 2024, the number of shareholders in Realcan Pharmaceutical Group (002589.SZ) was 79,066.
Realcan Pharmaceutical Group (002589.SZ) said on its investor interaction platform on July 30 that as of July 19, 2024, the number of shareholders in the company was 79,066.
Realcan Pharmaceutical Group (002589.SZ) has completed the layout of the production of medical instruments related to specific diseases such as diabetes and heart disease, as well as the research and development of new drugs.
Realcan pharmaceutical group (002589.SZ) stated on its investor interaction platform on July 29th that based on its advantages in network, scale, business model, and innovative layout accumulated over the years, it has established an efficient, lean, safe and smart distribution service system. On this basis, the company has extended its industry chain upstream and downstream. Realcan has completed the layout of medical device production fields related to specific diseases such as diabetes and heart disease as well as the new drug research and development field.
No Data
No Data